Conference being held October 7-9, 2024, in Phoenix, Arizona
MONTREAL, August 28, 2024 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell expansion and therapies, announced today that CEO David Millette will present in person at the annual Cell & Gene Meeting on the Mesa conference to be held from October 7-9, 2024 at the Arizona Biltmore Hotel in Phoenix, Arizona.
The presentation will provide an overview of the company, including:
- its proprietary technologies in cell and gene therapy, including molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of hematopoietic stem and progenitor cells (HSPCs); and
- clinical results, updates, near-term catalysts and commercial opportunities for UM171 Cell Therapy (INN/USAN-dorocubicel), which is now in late-stage development.
| Event: | ExCellThera Company Presentation |
| Date: | Monday, October 7, 2024 |
| Time: | 2:45 PM MT (5:45 PM ET) |
| Location: | Ballroom F, Arizona Biltmore Hotel, Phoenix, Arizona and livestream |
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.
About UM171 Cell Therapy
UM171 Cell Therapy (INN/USAN-dorocubicel), developed by Cordex Biologics, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients to treat hematologic malignancies in clinical trials in the United States, Europe and Canada. UM171 Cell Therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.
UM171 Cell Therapy has successfully completed Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with refractory or active disease, patients requiring a second transplant, and patients with TP53 mutations or other genetic abnormalities. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.
In Q2-2024, a Market Authorisation Application (MAA) for UM171 Cell Therapy has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for adult patients with hematological malignancies requiring a stem cell transplant who lack a readily available suitable donor.
The use of UM171 Cell Therapy in other patient populations, including patients with multiple myeloma, pediatric patients, and patients with non-malignant hematological diseases, is also being explored.
UM171 Cell Therapy is an investigational cell therapy, and its safety and efficacy have not been established by the FDA, EMA, Health Canada or any other health authority.
About ExCellThera and UM171 Technology
ExCellThera is a world leader in enhanced blood stem cell expansion. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding HSCs from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first- and best-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn.
